Skip to main content
TipRanks
Go Ultimate75% OFF

Sartorius (SRT) AI Stock Analysis

31 Followers
DE:SRT

Sartorius

(XETRA:SRT)

Select Model
Rating:62Neutral
Price Target:EUR 240.00â–²(6.43% Upside)
Action:reiterated
Date:10/27/26

The score is driven primarily by stable-but-not-peak financials (solid operating margins and improving free cash flow, but thin net margins, meaningful leverage, and weaker cash conversion). Technicals are supportive with a clear uptrend, though momentum is overbought. The latest earnings call was constructive with reaffirmed/raised guidance and improving profitability, but valuation is a major constraint due to a very high P/E and minimal yield.

Positive Factors
Recurring Consumables DemandStrong recurring consumables growth supports revenue visibility because customers repurchase products as biopharmaceutical batches run and production scales. This installed-process exposure can deepen customer retention and provide a durable base that is less dependent on individual equipment orders.
Negative Factors
Meaningful LeverageLeverage has improved but remains material, limiting financial flexibility relative to a lower-debt position. A sustained debt burden can constrain capital allocation and make the company more sensitive to weaker margins, slower demand, or the need to fund strategic investments.

Sartorius (SRT) vs. iShares MSCI Germany ETF (EWG)

-10%0%10%20%30%40%DE:SRT+29.12%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 15.52B
Dividend Yield
0.32%
Average Volume (3M)
3,627
Price to Earnings (P/E)
71.4
Beta (1Y)
1.16
Revenue Growth
4.19%
EPS Growth
63.32%
Country
Germany
Employees
14,042
Sector
General
Sector Strength
55
Industry
Medical - Instruments & Supplies

Sartorius Business Overview & Revenue Model

Company Description

Sartorius AG, founded in Göttingen, Germany in 1870, is a global supplier of advanced bioprocess solutions, laboratory products, and associated services. The company's diverse portfolio encompasses several critical areas: For biosensing and detection...

How the Company Makes Money

Sartorius makes money by selling products and services used repeatedly in bioprocessing and laboratory operations, with a business mix that typically combines (a) recurring consumables revenue and (b) capital equipment and systems revenue, complement...

Sartorius Earnings Call Summary

Earnings Call Date:Oct 22, 2026(Q3-2026)|% Change Since:7.64%|Next Earnings Date:Feb 23, 2027
Earnings Call SentimentPositive

The call was strongly positive overall. Management reported broad-based sales growth, continued recovery in equipment and non-recurring business, expanding margins, substantially higher free cash flow, lower leverage, and upgraded LPS guidance. The main challenges were tariff-related growth headwinds, pull-forward and timing effects in LPS, ATS project delays, difficult Q4 comparisons, FX pressure, and continued cyclicality in equipment demand. These lowlights were acknowledged but did not outweigh the operational, financial, and balance-sheet improvements.

Positive Updates

Solid Group Growth and Improved Profitability
Sartorius reported solid first-nine-month 2026 results, with both divisions contributing to growth. Underlying EBITDA increased 6.9% to EUR 828 million, and the underlying EBITDA margin expanded by 50 basis points to 30.2%, driven mainly by higher volumes and operating leverage.

Negative Updates

U.S. Academia and Government Activity Remains Below Prior Levels
Management said U.S. academia and government performance had improved slightly but was not at the levels seen in prior years.

Company Guidance

The company confirmed full-year operational sales growth broadly around the midpoint of the 5%-9% range for the group, 6%-10% for Bioprocess Solutions, and around the upper end of the 2%-6% range for Lab Products & Services; including customer compensation for tariff surcharges, growth in constant currencies is expected to be in the lower half of the respective guidance ranges for the group and BPS, and around the upper end of the range for LPS. Underlying EBITDA margin is expected to be slightly above 30% for the group, slightly above 32% for Bioprocess Solutions, and slightly above 21% for LPS. The full-year CapEx ratio expectation was lowered from around 12.5% to around 12%, net debt to underlying EBITDA remains expected at slightly above three times at year-end, MatTek’s contribution remains approximately 30 basis points for the group and 1.5 percentage points for LPS, tariff refund applications were approximately EUR 40 million with around EUR 31 million received by the end of September and the outstanding EUR 9 million expected by year-end, and FX is modeled as a headwind of slightly more than one percentage point on reported revenue growth for the full year and a tailwind of slightly below two percentage points in Q4. For Sartorius Stedim Biotech, operational growth is expected around the midpoint of the 6%-10% range, reported growth in constant currencies including customer compensation is expected to be in the lower half of this range, underlying EBITDA margin is expected to be slightly above 31%, the full-year CapEx ratio expectation was lowered from around 13.3% to around 13%, net debt to underlying EBITDA remains expected at slightly above two times at year-end, and FX headwind should be approximately 1.2 percentage points on reported revenue growth for the full year and a tailwind of approximately 1.7 percentage points in Q4.

Sartorius Financial Statement Overview

Summary

Stable but not peak performance. Revenue growth is modest (+2.32%) with solid operating profitability (TTM operating margin ~17.8%, EBITDA margin ~29.5%), but net margin is thin (~5.3%) versus 2021–2022. Leverage remains meaningful (debt-to-equity ~1.33) and cash conversion is a watch item (FCF to net income ~0.46) despite a rebound in free cash flow (€339M, +15.8%).

Income Statement

66Positive

Balance Sheet

58Neutral

Cash Flow

61Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.66B3.54B3.38B3.40B4.17B3.45B
Gross Profit1.66B1.64B1.52B1.57B2.20B1.84B
EBITDA1.08B1.07B786.80M873.20M1.54B945.12M
Net Income218.40M154.90M84.00M205.20M913.10M426.98M
Balance Sheet
Total Assets9.67B9.72B10.10B9.76B6.98B5.70B
Cash, Cash Equivalents and Short-Term Investments230.70M541.40M828.70M394.20M196.80M360.99M
Total Debt3.91B4.45B4.56B5.31B2.54B2.08B
Total Liabilities5.53B5.85B6.21B7.00B4.32B3.98B
Stockholders Equity2.93B2.71B2.76B2.07B1.99B1.26B
Cash Flow
Free Cash Flow351.70M214.10M566.30M293.90M211.60M458.65M
Operating Cash Flow750.60M656.00M976.20M853.60M734.20M865.81M
Investing Cash Flow-392.10M-513.50M-425.80M-2.82B-1.13B-569.61M
Financing Cash Flow-524.30M-410.60M-128.30M2.17B209.90M-165.18M

Sartorius Technical Analysis

Technical Analysis SentimentPositive
Last Price225.50

Price Trends

50DMA209.37Positive
100DMA198.98Positive
200DMA188.98Positive

Market Momentum

MACD5.35Positive
RSI57.00Neutral
STOCH43.63Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:SRT, the sentiment is Positive. The current price of 225.50 is above the 20-day moving average (MA) of 224.60, above the 50-day MA of 209.37, and above the 200-day MA of 188.98, indicating a bullish trend. The MACD of 5.35 indicates Positive momentum. The RSI at 57.00 is Neutral, neither overbought nor oversold. The STOCH value of 43.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:SRT.

Sartorius Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

DE:SRT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
DE:G1ADE:G1A80OutperformEUR 11.39B26.0117.46%1.84%5.37%9.46%
DE:EVKDE:EVK64NeutralEUR 9.94B56.312.16%4.69%1.98%83.13%
DE:SRTDE:SRT62NeutralEUR 17.83B71.367.81%0.32%4.19%63.32%
DE:PFVDE:PFV59NeutralEUR 1.57B23.2012.29%4.59%0.35%116.73%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
DE:SBSDE:SBS54NeutralEUR 339.15M-7.99-18.69%2.15%――
DE:GXIDE:GXI52NeutralEUR 1.07B-2.68-32.84%0.13%8.90%-609.05%

* General Sector Average

Performance Comparison

-25%0%25%50%DE:SRTDE:EVKDE:G1ADE:GXIDE:PFVDE:SBSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:SRT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:SRTSartorius (0NIQ)225.5044.8824.85%
DE:EVKEvonik Industries AG21.328.7669.69%
DE:G1AGEA Group AG70.5013.6824.07%
DE:GXIGerresheimer AG31.086.7427.69%
DE:PFVPfeiffer Vacuum Technology159.6010.487.03%
DE:SBSSTRATEC Biomedical27.907.9439.78%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 27, 2026